pleomorphic lobular carcinoma in situ of the breast a single institution experience with clinical follow-up and centralized pathology review.[2017]英文精品课件.pdf

Breast Cancer Res Treat DOI 10.1007/s10549-017-4334-1 EPIDEMIOLOGY Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review 1 2 2 1 Marina De Brot • Starr Koslow Mautner • Shirin Muhsen • Victor P. Andrade • 2 3 3 2 3 Anita Mamtani • Melissa Murray • Dilip Giri • Rita A. Sakr • Edi Brogi • Tari A. King4,5 Received: 1 June 2017 / Accepted: 7 June 2017 Springer Science+Business Media, LLC 2017 Abstract prior breast cancer history and those having mastectomy Purpose The natural history of pleomorphic lobular car- were excluded from outcome analysis. Among the cinoma in situ (PLCIS) remains largely unknown. remaining 7 patients with PLCIS/LCIS-PF, 4/7 (57%) Methods A pathology database search (1995–2012) was developed ipsilateral breast cancer at a median follow-up performed to identify patients diagnosed with an LCIS of 67 months. Median age at the time of breast cancer variant. Patients with synchronous breast cancer and/or no diagnosis was 56 years old and median time from PLCIS/ evidence of pleomorphism were excluded. Original slides LCIS-PF to cancer diagnosis was 59 months (range were re-evaluated by three pathologists to identify a con- 45–66 months). The four cancers included 1 invasive lob- sensus cohort of PLCIS. Borderline lesions with focal ular carcinoma (ILC), 1 microinvasive ILC, 1 invasive atypia were classified as LCIS with pleom